FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to pharmacogenetics, clinical pharmacology, psychiatry, narcology, and can be used to select the dosage of benzodiazepine of prolonged action of diazepam in patients with anxiety disorders. The substance of the invention consists in calculating the value of the parameter P, constituting an estimate of the degree of change in the rate of biotransformation of diazepam, depending on the state of genetic polymorphism in each individual patient.
EFFECT: technical result is estimation of the effectiveness of therapy with diazepam for treating patients with anxiety disorders.
1 cl, 1 tbl, 1 ex
